RhoBTB3 is a member of the RHOBTB subfamily of Rho GTPases that play a role in mediating cell size, proliferation, apoptosis, PI-103 survival, polarity, call adhesion and membrane trafficking. Recent studies have suggested that RhoB is involved in tumor suppression. These studies suggested that RhoB was detected in normal tissue yet its expression was dramatically lost during cancer progression in lung and head and neck squamous cell carcinoma. In line with these findings, high expression of RhoB was associated with favorable outcome in bladder cancer. In our study, we suggested that RhoBTB3 might serve as a potential tumor marker for good prognosis in USC. RAS association domain family 7 is located at 11p15.5 and it belongs to the Ras-domain family of ten members that are implicated in various cellular mechanisms including apoptosis, cell cycle control, and microtubule stabilization. They are downregulated by epigenetic mechanisms, indicating the potential role of a tumor suppressor gene. However, this does not currently exist in RASSF7. Recently RASSF7 was found in numerous tissues and knocking down RASSF7 function resulted in blocking spindle formation, triggering a mitotic arrest, nuclear breakdown and apoptosis. This suggests the possibility that RASSF7 could have a role in promoting cancer cell development. In our study the under-expression of RASSF7 in USC correlated with good prognosis and the detection of RASSF7 silencing by methylation study could have potential clinical use for USC prognosis and treatment. Finally, Fibulin1, mapped on 22q13.3 gene, belongs to a family of secreted glycoproteins. Fibulin family has been shown to modulate cell morphology, growth, adhesion and motility. In particular, FBLN1 appeared to have a role in inhibiting cell adhesion, spreading, motility and invasion in human cancer cells. In vivo studies showed increased FBLN1 expression in ovarian and breast carcinomas. Others had showed its downregulation in prostate and gastric cancer. Therefore, speculation still exists regarding FBLN1 as a tumor-suppressor gene or an oncogene or it might even have dual functions. In our study, the over-expression of the FBLN1 protein was observed for good prognosis in EAC. One limitation of this study is the relatively small sample size which does not provide us enough power for statistical analysis of expression levels of DEGs and clinical characteristics. The result should be interpreted with caution because of the small sample size and undetermined molecular mechanisms of novel DEGs. Nevertheless, novel DEGs found in our studies, once narrowed down and verified in future studies with larger cohort, might have potential prognostic and therapeutic effects in each of EAC and USC. In conclusion, although the sample size was small for a definite conclusion, we believe that our findings shed meaningful insights into the clinical study of endometrial cancer patients that warrant further investigation.